Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI
NCT04861077Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2027
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluoromisonidazole in triple-negative breast cancer (TNBC), sponsored by University of Alabama at Birmingham. Primary endpoints: PET standardized uptake value and Apparent diffusion coefficient. Planned start Jun 2027; status: recruiting.
02
Drugs
fluoromisonidazole
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04861077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861077.